Use of DNA microarray and small animal positron emission tomography in preclinical drug evaluation of RAF265, a novel B-Raf/VEGFR-2 inhibitor.

@article{Tseng2011UseOD,
  title={Use of DNA microarray and small animal positron emission tomography in preclinical drug evaluation of RAF265, a novel B-Raf/VEGFR-2 inhibitor.},
  author={Jeffrey R. Tseng and Darrin Stuart and Kimberly Aardalen and Angelo Kaplan and Natasha A Aziz and Nicholas P. Hughes and Sanjiv Sam Gambhir},
  journal={Neoplasia},
  year={2011},
  volume={13 3},
  pages={266-75}
}
Positron emission tomography (PET) imaging has become a useful tool for assessing early biologic response to cancer therapy and may be particularly useful in the development of new cancer therapeutics. RAF265, a novel B-Raf/vascular endothelial growth factor receptor-2 inhibitor, was evaluated in the preclinical setting for its ability to inhibit the uptake of PET tracers in the A375M(B-Raf(V600E)) human melanoma cell line. RAF265 inhibited 2-deoxy-2-[(18)F]fluoro-d-glucose (FDG) accumulation… CONTINUE READING